Predict S.p.a. Class B · MIL:PRE
Predict S.p.a. Class B — IR TOP Lugano Investor Day 2026
19 slides from Predict S.p.a. Class B's conference presentation, Oct 9, 2026
Slide 1: Predict S.p.A. Investor Presentation
PREDICT S.p.A. Investor Presentation 9th October 2026 IR TOP Lugano Investor Day 2026
Slide 2: At a Glance
AT A GLANCE Hi-Tech solutions for advanced diagnostics ~20years 33 Predict S.p.A., based in Bari, is an innovative SME active in the Highly of partnership med-tech sector, specializing in non-invasive in vivo diagnostics. qualified with GE €0.84mn employees* It markets medical imaging systems for sc
Slide 3: Milestones
MILESTONES DISTRIBUTION AGREEMENTS Shenzhen Spinq | Airs Medical EU | UVC Solutions | Caresmed ORDERS/CONTRACTS 2 Mistral Samplers+services (IRCCS Bari) | MQ Analyzer (DIF Bari) | 2 Mistral Samplers PoliBA | 3 2026 Robots Corporea Museum (NA) | LiberAUT Project | RTI Tender «AMiCa» | Fetal ultrasoun
Slide 4: Industry Business System and Business Model
INDUSTRY BUSINESS SYSTEM AND BUSINESS MODEL Predict offers a model based on the supply of innovative and high-tech solutions for the healthcare sector, ensuring a favorable ecosystem for widespread technological innovation processes. UNIVERSITIES PATIENTS SUPPLIERS IRCCS CUSTOMERS AND CITIZENS HOSPI
Slide 5: Strategic Business Units
STRATEGIC BUSINESS UNITS The activities of Predict are divided into 4 Strategic Business Units: Traditional Innovative SBU Imaging People Support Mistral Digital Healthcare • Sale of medical imaging • Technical support for • Development, design & • Development and sale of equipment*, marketed in the
Slide 6: Products and Application Portfolio
PRODUCTS AND APPLICATION PORTFOLIO Predict is unique on the national scene, ensuring technological oversight of health data collected through medical devices and the developed equipment. Traditional Innovative SBU Imaging People Support Mistral Digital Healthcare Mistral Sampler Optip Surgery Optip
Slide 7: Research and Development
RESEARCH AND DEVELOPMENT • FY24: Qualitative and semi-quantitative identification of a set of molecules representative of the pathologies investigated; start of clinical trials for other studies MISTRAL • FY25: Clinical trials on asthma, pilot study on head and neck cancers, development of AI-based
Slide 8: Patents and CE Trademarks
PATENTS AND CE TRADEMARKS 12/2025 Filing of Italian patent application for Optip Nuva 08/2017 09/2021 Filing of European patent application 12/2019 Patent granted in the USA, Filing of CE trademark no. 11,122,164 B2 08/2018 02/2020 03/2023 2026 Filing of international PCT patent Filing of CE tradema
Slide 9: Reference Markets and Drivers
REFERENCE MARKETS AND DRIVERS Predict operates in 3 market niches in the Healthcare sector, growing globally: 1 Imaging 2 Breath analysis 3 Digital Health Tech A t I n t e r n a t i o n a l l e v e l +5% $ bn +23% $ bn CAGR 2026-2033 +17% $ bn CAGR 2026-2033 CAGR 2023-2030 1.830 65 9 46 3 347 2026 2
Slide 10: Management Team & Key People
MANAGEMENT TEAM & KEY PEOPLE Isabella Cafagna Loredana Amoruso Angelo Gigante Vice President and CEO CEO Founder, President, CEO Director SBU Mistral, SBU Digital Healthcare Tender and Legal Affairs Manager 20+ years of experience 10+ years of experience 10+ years of experience 2008: founds Predict
Slide 11: Shareholding and Governance
SHAREHOLDING AND GOVERNANCE SHAREHOLDING GOVERNANCE Board of Directors** Angelo Aurelio Paola Angelo Aurelio Gigante Gigante Sciancalepore President and CEO Isabella Cafagna Loredana Amoruso 51% 49% Vice President, Executive Director Executive Director Rocco Dichio Valeria Stucci Treasury Other Dire
Slide 12: Growth Strategies
GROWTH STRATEGIES Development of § R&D, partnerships with clinical research centers and university TTOs § Hiring of new professional roles, strengthening of commercial functions, innovative SBUs and product development with a focus on § Roll-out of a network of Mistral Labs in Italy Mistral § Develo
Slide 13: Financial Highlights 1H26
FINANCIAL HIGHLIGHTS 1H26 Revenue / VoP (€mn) EBITDA (€mn) Net Result (€mn) NFI / NFI Adj.* (€mn) Equity (€mn) 13 *Adjustments attributable to receivables accrued under the regional PIA project, unchanged vs. 31/12/2025
Slide 14: Investment Highlights
INVESTMENT HIGHLIGHTS High-growth markets in Healthcare Strong demand for diagnostic technologies, leading to efficient offerings at lower costs "Turnkey" solutions High level of know-how and track record for breath analysis laboratories at University acquired by top management, Hospitals, IRCCS, an
Slide 15: Predict on EGM
PREDICT ON EGM Market data IDENTIFIERS & STOCK Stock code PRE ISIN Ordinary Shares IT0005611071 N. Ordinary Shares 5,869,000 N. Multiple voting shares1 1,800,000 N. PAS2 60,000 IPO DATA Start date of trading 30/09/2024 Capital raised in IPO (pre greenshoe) € 1,519,500 Admission price € 1.00 IPO capi
Slide 16: Annex
LIFE CARE ANNEX
Slide 17: Financial Highlights FY25 vs FY24 & FY23
FINANCIAL HIGHLIGHTS FY25 vs FY24 & FY23 Revenue / VoP (€mn) EBITDA (€mn) Net Result (€mn) EBITDA% FY25: 10.3% (vs.12.2% FY24) NFI / NFI Adj. (€mn) Equity (€mn) 17
Slide 18: Disclaimer
DISCLAIMER This document has been prepared by Predict S.p.A. (the "Company") for informational purposes only. It contains only summarized information and, therefore, is of a preliminary nature. Additionally, it has been prepared without claiming to be exhaustive. This presentation ("Presentation") a
Slide 19: Predict Investor Relations
PREDICT Bari Viale Adriatico, 4 c/o Fiera del Levante - Pad. 105 | +39 080 893 3754 Milano Piazza Gae Aulenti 1, Torre B | +39 02 9713 0325 Roma Via Marsala 29H | +39 06 4547 3124 predictcare.it INVESTOR RELATIONS MANAGER INVESTOR RELATIONS ADVISOR Angelo Ceci, CFO & IRM - Predict Chiara Cardelli, S